SANA

Sana Biotechnology, Inc. (SANA) Business Model Analysis (2026)

Invetso Score: 2.8/10 — Weak · Last Updated: 2026-08-01

Overall Score

Revenue Model

No meaningful revenue generation is reflected in the latest TTM metrics, with revenue per share at 0 and price-to-sales at 0.

The business remains pre-commercial or too early-stage for a stable recurring revenue model to be evidenced in the current data.

Profitability

TTM margins are effectively 0 across gross, operating, EBITDA, pretax, and net profit, indicating no current operating profitability.

Returns remain deeply negative, including ROA of -49.1%, ROE of -134.5%, and ROIC of -64.5%.

Cash Generation

Operating cash flow and free cash flow are both negative, with free cash flow per share at -0.457 and FCF yield at -11.8%.

Cash conversion remains poor despite low capex intensity, as operating cash flow is negative and the company is not self-funding.

Balance Sheet

Liquidity is acceptable with a current ratio of 1.38 and cash ratio of 0.46, suggesting near-term obligations are covered.

Leverage is moderate with debt-to-equity at 0.48 and debt-to-assets at 0.17, but the negative solvency ratio and negative tangible book value temper the balance-sheet profile.

Capital Efficiency

Capital efficiency is very weak, with return on invested capital at -64.5% and return on capital employed at -67.6%.

Negative asset turnover and negative earnings yield indicate the asset base is not yet producing economic returns.

Sources

  • Company filings (10-K, 10-Q, investor presentations)
  • Financial and market data providers
  • Public news and industry information

🔒 Go Beyond This Framework

This is one of 10 institutional-grade frameworks Invetso runs on Sana Biotechnology, Inc.. Unlock the complete analysis — SWOT, Economic Moat, Porter’s Five Forces, Management, PESTLE and the Invetso Quality Score.

Create your free account on Invetso →